abstract the invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the tgf-beta1, tgf-beta2 or tgf-beta3 nucleic acid sequence, which comprises modified nucleotides such as lna, ena, polyalkylene oxide-, 2'- fluoro, 2'-o-methoxy and / or 2'-o-methyl modified nucleotides. the selected regions are preferably the region of nucleic acid no. 1380 to 1510, no. 1660 to 1680, no. 2390 to 2410, or no. 2740 to 2810 of the tgf-beta2 nucleic acid sequence of seq id no. 1, specific regions of the tgf-beta1 nucleic acid sequence of sequence id no. 149, or specific regions of the tgf-beta3 nucleic acid sequence of sequence id. 267. the invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in the prevention and / or treatment of a malignant and / or benign tumor, an immunologic disease, fibrosis, glaucoma, etc. abstract translation patent summary: "modified tgf-beta oligonucleotides". The invention relates to an oligonucleotide consisting of 10 to 20 nucleotides from selected regions of the tgf-beta1, tgf-beta2 or tgf-beta3 nucleic acid sequence which comprises modified nucleotides such as nucleotides lna, ena, polyalkylene oxide, Modified 2'-fluorine, 2'-o-methoxy and / or 2'-o-methyl. the regions selected are preferably nucleic acid region no. 1380 to 1510, no. 1660 to 1680, no. 2390 to 2410, or no. 2740 to 2810 of the tgf-beta2 nucleic acid sequence of seq id # 1 , specific regions of the tgf-beta1 nucleic acid sequence of sequence id 149, or specific regions of the nucleic acid sequence of sequence id 267. The invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used for the prevention and / or treatment of a malignant and / or benign tumor, an immune disease, fibrosis, glaucoma, etc.abstract the invention refers to an oligonucleotide consisting of 10 to 20 nuc
